-
Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
23 Apr 2024 17:43 GMT
… treatment for non-small cell lung cancer. News release. BeiGene, … squamous non–small-cell lung cancer: a phase 3 randomized … et al. Tislelizumab versus docetaxel in patients with previously … treatment for non-small cell lung cancer. News release. BeiGene, Ltd …
-
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
23 Apr 2024 10:17 GMT
… treatment for non-small cell lung cancer (NSCLC) across three indications … .
“Non-small cell lung cancer remains one of the … trial with tislelizumab versus docetaxel that enrolled 805 patients … lung cancers.2 In 2020, the number of new cases of lung cancer …
-
EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer
20 Apr 2024 12:31 GMT
… lung cancer: current treatment and future advances. Transl Lung Cancer Res … with small-cell lung cancer. Clin Lung Cancer. 2003;5(2 … al. Non-small-cell lung cancers: a heterogeneous set of … of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles …
-
Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
11 Apr 2024 16:52 GMT
… for non-small-cell lung cancer (NSCLC) patients ineligible … 7,8 of all lung cancers cases, with nearly … -cell lung cancer: a cost-effectiveness analysis. Translational Lung Cancer Res. … docetaxel in patients with previously treated non-small-cell lung cancer …
-
Tecentriq, Cabometyx May Not Improve Survival Over Chemo in NSCLC
23 Apr 2024 22:04 GMT
… therapies for subtypes of lung cancer with particular mutations, … for non-small cell lung cancer, sometimes in combination … plus Cabometyx (cabozantinib) versus docetaxel among patients with metastatic … non-small cell lung cancer did significantly better …
-
EC approves BeiGene’s tislelizumab for three NSCLC indications
23 Apr 2024 18:44 GMT
… treatment for non-small cell lung cancer (NSCLC). Tislelizumab, which is greenlit … NSCLC compared to treatment with docetaxel.
The most commonly reported Grade …
-
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
25 Mar 2024 10:25 GMT
… non-small-cell lung cancer. Clin Lung Cancer. 2021;22(1 … versus docetaxel in previously treated non-small-cell lung cancer. J … non-small-cell lung cancer patients. Clin Lung Cancer. 2020;21( … non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015; …
-
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
04 Mar 2024 10:29 GMT
… nonsquamous non-small cell lung cancer (NSCLC) who require … of datopotamab deruxtecan versus docetaxel in patients with locally … -Small Cell Lung Cancer
Nearly 500,000 lung cancer cases were …
References:
1 Cancer.net. Lung Cancer – Non-Small Cell: Statistics …
-
Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer
04 Mar 2024 08:08 GMT
… nonsquamous non-small cell lung cancer (NSCLC) who require … for datopotamab deruxtecan in lung cancer and breast cancer are … non-small cell lung cancer
Nearly 500,000 lung cancer cases were … of datopotamab deruxtecan versus docetaxel in patients with locally …
-
Docetaxel Market is Booming Worldwide | Beijing Union Pharmaceutical, Phyton, Actavis
25 Mar 2024 15:29 GMT
… is the Docetaxel Market?
The Docetaxel Market refers … and, region.
Global Docetaxel Market Breakdown by Type … cancer, Non-small cell lung cancer, Gastric cancer) by …
• Docetaxel Market Outlook (2024-2030)
• Docetaxel Market Trends
• Docetaxel Market …